Literature DB >> 30029581

Prevalence of Anaplasma phagocytophilum in humans in Belgium for the period 2013-2016.

Mony Hing1, Dorien Van Den Bossche1, Tinne Lernout2, Christel Cochez3, Jean-Paul Pirnay4, Walter Heuninckx1.   

Abstract

Ticks are vectors for a broad range of pathogens of medical and veterinary importance, such as Borrelia spp., Babesia spp., Anaplasma spp., Rickettsia spp., Bartonella spp. and the tick-borne encephalitis virus. The Gram-negative bacterium Anaplasma phagocytophilum is present worldwide, including Belgium where numerous patients were shown to harbour antibodies against this pathogen as recorded by the Belgian National Reference Center (NRC) for Anaplasma. The clinical presentation of human granulocytic anaplasmosis is an acute, febrile, nonspecific, flu-like illness. Leukopenia, thrombocytopenia and increased hepatic transaminase activities are commonly present early in the disease. Diagnosis early in the course of infection relies on the detection of antibodies or of the bacterium in the blood, as is performed at the NRC for Anaplasma, part of the Clinical Laboratory of the Queen Astrid Military Hospital in Brussels, Belgium. In this article, we discuss diagnostic test results as well as recent clinical and demographic characteristics of patients whose samples were analyzed by the NRC for Anaplasma in a four-year period (2013-2016).

Entities:  

Keywords:  Anaplasma phagocytophilum; clinical management; diagnostic testing; human granulocytic anaplasmosis

Mesh:

Substances:

Year:  2018        PMID: 30029581     DOI: 10.1080/17843286.2018.1491928

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  1 in total

1.  No molecular detection of tick-borne pathogens in the blood of patients with erythema migrans in Belgium.

Authors:  Laurence Geebelen; Tinne Lernout; Katrien Tersago; Sanne Terryn; Joppe W Hovius; Arieke Docters van Leeuwen; Steven Van Gucht; Niko Speybroeck; Hein Sprong
Journal:  Parasit Vectors       Date:  2022-01-20       Impact factor: 3.876

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.